Thus, patients whose tumours contain low levels of both SK1 and S1P4 have a mean disease-specific survival of 11.9 years compared with 7.95 years in patients with tumours that contain high SK1 or S1P4 expression (Figure 3C). Here, SPHK1 is linked to neoplasm.